Author: Ravi Shankar

• TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile supportive of systemic administration in an outpatient setting
• With median follow-up of 12.7 months, objective response rate (ORR) for the squamous cohort was 72% and disease control rate (DCR) was 100%, with a median duration of response of 12.9 months and multiple participants continuing in active follow-up
• TeLuRide-008, an ongoing adaptive Phase 2/3 trial of EIK1001 in NSCLC, actively enrolling, with a prespecified interim analysis for dose selection anticipated in 2H 2027

MILLBRAE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) — Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the presentation of updated data for EIK1001 at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.

“These updated results presented at ESMO from the squamous NSCLC cohort build on the mature non-squamous cohort data presented at ASCO and further support the potential of adding EIK1001 to pembrolizumab and chemotherapy,” said Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon. “The observed response and disease control rates, as well as a 12.9-month median duration of response, are encouraging, with several patients remaining in active follow-up. These findings support continued evaluation of this combination for patients with advanced NSCLC.”

EIK1001 Clinical Update:

Updated data from the open-label TeLuRide-005 trial evaluating TLR7/8 dual-agonist EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy in participants with advanced NSCLC demonstrates potentially durable effect of EIK1001 in combination with standard of care, as well as a tolerability profile supportive of systemic administration in an outpatient setting, a potential key differentiator of EIK1001 from previous TLR7/8 targeted therapies.

In TeLuRide-005, 72 participants with previously untreated stage 4 NSCLC received intravenous EIK1001 once-weekly (QW) combined with standard of care pembrolizumab plus histology-appropriate chemotherapy once every third week (Q3W). After 8 cycles, EIK1001 administration was reduced to Q3W. The maximum treatment duration is 2 years (up to 35 cycles) for EIK1001 in combination with pembrolizumab, with pemetrexed continued at the discretion of the Investigator for non-squamous participants.

At the July 13, 2026, safety data cutoff, among the safety evaluable population (n=72: 39 non-squamous; 33 squamous), the combination of EIK1001 with pembrolizumab and chemotherapy was generally well tolerated, with an adverse event (AE) profile similar to standard-of-care alone. Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 48.6% of participants, and TRAEs led to treatment discontinuation in 6.9%. The most common Grade 3 or higher TRAEs were neutropenia (30.6%), anemia (9.7%), and thrombocytopenia (9.7%). Cytokine release syndrome events were all low-grade (Grade 1, n=5; Grade 2, n=2), and there were no Grade 3 or higher events. There were no TRAEs that led to death. This profile was sufficient to support administration in an outpatient setting during the ongoing trial.

Among the efficacy-evaluable population (n=65: 36 non-squamous; 29 squamous), EIK1001 treatment in combination with pembrolizumab and chemotherapy pooled data with a median follow-up of 17.2 months resulted in a 63.1% objective response rate (ORR) and 89.2% disease control rate (DCR) at the efficacy data cutoff of October 1, 2026. Objective responses were observed across all PD-L1 tumor proportion score (TPS) subgroups. Among participants in the squamous cohort, an ORR of 72.4% and a DCR of 100% were observed, respectively, with a median follow-up of 12.7 months and a median duration of response (DOR) of 12.9 months at the efficacy data cutoff. Among participants in the non-squamous cohort, an ORR of 55.6% and a DCR of 80.6% were observed, respectively, with a median follow-up of 17.9 months. The median DOR in the non-squamous cohort was 11.2 months at the efficacy data cutoff.

In addition to the TeLuRide-005 data presented at ESMO, Eikon is currently conducting a Phase 2/3 registrational trial of EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy in systemic therapy-naïve participants with stage 4 non-squamous or squamous NSCLC, also known as TeLuRide-008 (NCT07365319). Eikon expects to conduct a first interim analysis to select the single dose of EIK1001 to take forward for the remainder of this trial in the second half of 2027.

About Eikon Therapeutics
Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com.

About NSCLC
Lung cancer is one of the most common cancers globally, with NSCLC making up 80% to 85% of all lung cancer cases. NSCLC is often diagnosed at advanced stages when treatment options are more limited and there remains significant unmet medical need in this patient population. The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The current standard of care for stage 4 NSCLC, combining immune checkpoint inhibitors (ICIs) (e.g., pembrolizumab) plus histology-appropriate chemotherapy confers significant clinical benefit over chemotherapy alone, yet many patients progress nonetheless, highlighting the large unmet medical need in the management of this disease.

About EIK1001
EIK1001 is an investigational, systemically administered dual-agonist of Toll-like receptors 7 and 8, designed to stimulate both innate and adaptive immune responses. In Phase 1 trials of EIK1001, single-agent activity was observed in patients with advanced malignancy. This mechanism may complement the anti-tumor immune response engendered by PD-(L)1 blockade. EIK1001 has been studied in over 600 participants and observed to be well-tolerated to date, both as a monotherapy and in combination with PD-(L)1-specific antibody-based therapy.

About TeLuRide-005
TeLuRide-005 (NCT06246110) is a multicenter, open-label trial of once-weekly (QW) systemically administered EIK1001 in combination with standard of care, once every third week (Q3W) pembrolizumab and histology-appropriate chemotherapy in first-line, treatment-naïve participants with stage 4 NSCLC. Enrollment completed in the first quarter of 2026.

Forward-Looking/Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon’s product candidates; the potential to further develop Eikon’s product candidates; the timing for anticipated data readouts; expected milestones and business objectives, including Eikon’s anticipated presentations at the 2026 ESMO Congress; and other statements regarding Eikon’s future operations, financial performance, financial position, prospects, objectives, strategies and other future events.

These forward-looking statements are based upon management’s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption “Risk Factors” and elsewhere in Eikon’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission (“SEC”) on August 13, 2026, and in other public filings with the SEC in the future.

As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts:

Investors
Alfred “Freddie” Bowie, Ph.D., CFO
ir@eikontx.com

Media
Colin Sanford
colin@bioscribe.com

VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) — SNOWLINE GOLD CORP. (TSX: SGD) (US OTCQB: SNWGF) (the “Company” or “Snowline”) is pleased to announce the appointment of Randy Smallwood to its Board of Directors (the “Board”) as an Independent Director, effective today. Mr. Smallwood brings further mining, corporate development and finance experience to Snowline’s Board. He is the non-executive Chair of Wheaton Precious Metals Corp. (“Wheaton”) where, as President and CEO he led the company through a period of remarkable growth from 2011 to 2026.

“We are pleased to welcome Randy to our Board as a recognized builder in the gold industry,” said Craig Hart, Chair of Snowline’s Board. “His several decades of experience will bring new dimensions of expertise to our Board.”

“Mr. Smallwood’s reputation as an entrepreneur and corporate leader in our industry is well earned, and he adds valuable perspective as Snowline continues to advance and grow,” said Scott Berdahl, CEO. “Importantly, his longstanding commitment to responsible development, community investment and philanthropy strongly align with the values that guide Snowline.”

“I am excited about the opportunity to join the Snowline team and to help them advance the Rogue Project,” said Mr. Smallwood. “The Valley deposit has the potential to become one of Canada’s largest gold mines and a major contributor to the Yukon economy.”

Mr. Smallwood was a co-founder of Wheaton (formerly Silver Wheaton Corp.) in 2004 and served as President and CEO from 2011 to March 2026. Previously he led project evaluation and corporate development for Wheaton River Minerals Ltd./Goldcorp and was Project Manager for the Golden Bear Mine in northern B.C. from 1995 to 2000.

He remains active on the World Gold Council, having served as Chair (2020-2023), and with the Canadian Institute of Mining, Metallurgy and Petroleum (CIM) where he is the incoming President-Elect.

Randy’s commitment to the community includes his support of various philanthropic endeavours with Special Olympics BC, MineralsEd BC, and Mining4Life, and previously the BC Cancer Foundation board.

Mr. Smallwood holds a geological engineering degree (1995) and an Alumni Medal of Distinction (2026) from the University of British Columbia, along with a mine engineering diploma (1992) and a Distinguished Alumni Award (2015) from the British Columbia Institute of Technology.

ABOUT SNOWLINE GOLD CORP.

Snowline Gold Corp. is a Yukon Territory gold exploration and development company focused on advancing its 100% owned Valley gold deposit on its flagship Rogue Project, while unlocking district upside on its 360,000 ha (3,600 km²) mineral tenure in the highly prospective yet underexplored Selwyn Basin.

Valley is a large, low strip, near surface, >1 g/t Au bulk tonnage gold system hosting an open MRE of 7.94 million ounces gold at 1.21 g/t Au Measured & Indicated (in 204.0 million tonnes)¹ and an additional 0.89 million ounces gold Inferred at 0.62 g/t Au (in 44.5 million tonnes)², with a cut-off grade of 0.3 g/t Au. Results of a PEA for Valley suggest the potential to support a long-life mining operation with a strong production profile and low production costs. The MRE and PEA are detailed in the recent technical report for Rogue, prepared in accordance with NI 43-101 (as defined below) standards, entitled “Independent Preliminary Economic Assessment for the Rogue Project Yukon, Canada,” dated August 27, 2025, with an effective date of March 1, 2025, and available on SEDAR+ and the Company’s website (the “Technical Report”). The PEA is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have economic considerations applied to them that would enable classification as Mineral Reserves. There is no certainty that the results of the PEA will be realized. Work is underway on a PFS to supersede the Valley PEA on completion, anticipated in Q1 2027.

Snowline’s project portfolio sits within the prolific Tintina Gold Province, host to multiple million-ounce-plus gold mines and deposits across the central Yukon and Alaska. The Company’s comprehensive first-mover position and extensive exploration database provide a distinct competitive advantage and a unique opportunity for investors to be part of multiple discoveries, the advancement of a significant gold deposit, and the creation of a new gold district.

QUALIFIED PERSON

Information in this news release has been prepared under supervision of and approved by Thomas Branson, M.Sc., P. Geo., VP Exploration for Snowline, as Qualified Person for the purposes of NI 43-101.

ON BEHALF OF THE BOARD

Craig Hart
Independent Chair & Director

Scott Berdahl
CEO & Director

For further information, please contact:

Snowline Gold Corp.
+1 778 650 5485
info@snowlinegold.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release contains certain forward-looking statements, including statements regarding advancement of the Valley deposit and the Rogue Project; Valley’s potential to become one of Canada’s largest gold mines and a major contributor to the Yukon economy; the potential for a long-life mining operation with a strong production profile and low production costs; the anticipated completion of the PFS in Q1 2027; continued exploration; potential discoveries; and the creation of a new gold district. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. Such factors include, among other things: risks related to uncertainties inherent in drill results and the estimation of mineral resources; and risks associated with executing the Company’s plans and intentions. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

                            

¹ Comprising 3.15 million ounces at 1.41 g/t Au in Measured and 4.79 million ounces at 1.11 g/t Au in Indicated.

² Mineral resources are not mineral reserves and do not have demonstrated economic viability. The estimate of mineral resources may be materially affected by metal prices, economic factors, environmental, permitting, legal, title, or other relevant issues.

Press Release

Atos launches Atos Genesis Intelligence suite featuring Atos Codex to address the full AI application spectrum

As the culmination of the Atos Genesis Intelligence suite, Atos Codex turns operational data into trusted real-time decisions and actions for mission-critical environments.

Paris, France, October 26, 2026 – Atos, a global leader in digital transformation and artificial intelligence, today announces Atos Genesis Intelligence, a comprehensive AI suite designed to help organizations accelerate AI adoption and transform data into measurable business outcomes. By bringing together sovereign data management, advanced AI capabilities, secure orchestration and governance within a single ecosystem, the suite enables enterprises to move faster from experimentation to production, simplify complex technology landscapes and scale trusted and frugal AI across the full spectrum of critical business operations.

Built for organizations operating in highly regulated and data-sensitive environments, Atos Genesis Intelligence provides the foundation to innovate faster, improve decision-making, increase operational efficiency and maintain full control over data, infrastructure and compliance requirements. Deployable across public cloud, sovereign cloud, on-premises and air-gapped environments, the suite combines flexibility, security and sovereignty without compromise.

Bridging the gap between AI insights and mission-critical operational outcomes with Atos Codex

Alongside the suite, Atos is introducing Atos Codex, the ultimate expression of Atos Genesis Intelligence. Atos Codex, which stands for Center of Operations and Data EXcellence, is designed for organizations operating in mission-critical environments, and transforms data, expertise and AI insights into trusted actions executed within a secure and governed environment.

While many AI initiatives stop at recommendations, Atos Codex helps organizations move from knowing to acting. By connecting data, operational context, cybersecurity controls and AI-driven reasoning within a single platform, it enables faster, more informed and more consistent decision-making across mission-critical operations.

Built on Atos’ decades of experience operating some of the world’s most complex and sensitive environments, as well as on Eviden’s expertise in cybersecurity products and mission-critical systems, the platform helps critical infrastructure operators, transportation providers, industrial organizations, defense agencies and public sector institutions improve responsiveness, optimize operations and strengthen resilience while maintaining human oversight and governance.

By continuously connecting information, context, intelligence and execution, Atos Codex enables organizations to shorten decision cycles, improve operational performance, and react more effectively to changing conditions. The result is greater operational agility, stronger resilience, and better business outcomes delivered within a secure and governed framework.

Atos Codex creates a structured representation of the organization’s operational environment including its entities, relationships, rules, permissions and possible actions – an operational ontology that provides a shared context for users, data and AI.  Insights and decisions can then be translated into operational actions, based on the governance model and the level of human control defined by the organization.  

“Organizations are looking beyond AI experimentation and increasingly focusing on tangible business outcomes. With Atos Genesis Intelligence, we provide an end-to-end sovereign and trusted foundation that helps our customers accelerate AI adoption, reduce complexity and deliver measurable value faster across the full AI lifecycle. As the culmination of the suite, Atos Codex extends this vision by enabling mission-critical organizations to turn trusted insights into operational actions, helping them become more efficient, resilient and competitive while maintaining full control over their critical data and operations,” said Philippe Salle, Chairman and CEO of Atos Group.

More information about Atos Genesis Intelligence suite

Atos Genesis Intelligence is a comprehensive end-to-end AI suite designed to help organizations accelerate AI adoption while maintaining sovereignty, security and governance across the entire AI lifecycle. Combining data management, AI model development and deployment, and orchestration capabilities within a single ecosystem, the suite provides the foundation required to industrialize AI initiatives, reduce deployment risks and scale them across the enterprise.

Key features include:

• Open and interoperable architecture, built on open-source technologies to provide flexibility, avoid vendor lock-in and accelerate innovation.
• Sovereign and flexible deployment options, supporting public cloud, sovereign cloud, on-premises and air-gapped infrastructures to meet the requirements of highly regulated organizations.
• Data Foundation for unifying and governing data throughout its lifecycle, from ingestion and preparation to transformation and analytics, with built-in data quality, cataloging, lineage and traceability.
• Enterprise-grade AI capabilities combining intelligent model routing and cost optimization to enable a more frugal use of AI, with secure AI orchestration and integrated governance, security and compliance controls.
• SLM Factory (Small Language Model Factory) for developing and managing locally deployable AI models, giving organizations greater control over their data and AI environments.
• Enterprise AI portal, providing secure access to a marketplace of GenAI agents that can be customized for specific business use cases.

The Atos Genesis Intelligence Suite is continuously enriched through the Atos Sovereign Agentic Studios, a global, production-first delivery model for real-world agentic AI deployment, incorporating field-proven innovations, accelerators and best practices.

***

About Atos

Atos is Atos Group’s brand dedicated to end-to-end, secure and AI-accelerated digital services. Atos designs, develops and operates digital environments that are critical to performance, resilience and sovereignty. The company helps public and private organizations around the world maintain control of their data and infrastructure, while meeting their compliance requirements.

With more than 51,000 employees serving more than 4,500 customers in 54 countries, Atos supports the modernization of IT systems, accelerates cloud and data transformation, strengthens cybersecurity and deploys secure digital workplaces for the benefit of its customers, their employees and society. Atos also offers consulting and support services through its Atos Amplify brand.

As a trusted partner in the management of complex and critical environments, Atos supports organizations in highly regulated and sovereign contexts.

About Atos Group

Atos Group is a global leader in digital transformation with nearly 53,000 employees and annual revenues of nearly €7.2 billion. With a commercial presence in 54 countries, it operates under two brands: Atos for services and Eviden for products and systems. As the European leader in cybersecurity and a leader in the cloud sector, Atos Group is committed to a secure and decarbonized future. It offers tailor-made and integrated solutions, accelerated by AI, for all sectors of activity. Atos Group is listed on Euronext Paris.

Press contact: Laurent Massicot – laurent.massicot@atosgroup.com

Attachment

• Global PR – Atos launches Atos Genesis Intelligence suite featuring Atos Codex to address the full AI application spectrum

ANNOUNCEMENT

A.P. Møller – Mærsk A/S – Transactions in connection with share buy-back program

On 5 February 2026, A.P. Møller – Mærsk A/S (the “Company”) announced a share buy-back program of up to DKK 6.3bn (around USD 1bn) to be executed over a period of 12 months. The second phase of the share buy-back program will run from 13 August 2026 up to 29 January 2027. The shares to be acquired will be limited to a total market value of DKK 3.15 billion (around USD 500m).

The share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”)

The following transactions have been made under the program in the period 19 October to 23 October 2026:                        

	Number of A shares	Average purchase price A shares, DKK	Transaction value, A shares, DKK
Accumulated, last announcement	50,148		861,977,700
19 October 2026	220	23,631.3636	5,198,900
20 October 2026	220	23,321.1818	5,130,660
21 October 2026	220	22,834.9091	5,023,680
22 October 2026	220	22,440.2727	4,936,860
23 October 2026	220	21,998.9091	4,839,760
Total 19-23 October 2026	1,100		25,129,860
Accumulated in the second phase of the program	13,000		284,753,190
Accumulated under the program	51,248		887,107,560
	Number of B shares	Average purchase price B shares, DKK	Transaction value, B shares, DKK
Accumulated, last announcement (market and the Foundation)	200,592		3,536,107,145
19 October 2026	771	24,490.9598	18,882,530
20 October 2026	771	24,160.9079	18,628,060
21 October 2026	771	23,518.8586	18,133,040
22 October 2026	771	23,145.2529	17,844,990
23 October 2026	771	22,655.5123	17,467,400
Total 19-23 October 2026	3,855		90,956,020
Bought from the Foundation*	545	23,594.2983	12,858,893
Accumulated in the second phase of the program (market and the Foundation)	52,000		1,182,053,783
Accumulated under the program (market and the Foundation)	204,992		3,639,922,058

*) According to a separate agreement, A.P. Møller og Hustru Chastine Mc-Kinney Møllers Familiefond (the Foundation) participates on a pro rata basis to the shares purchased in the share buy-back program.

With the transactions stated above, the Company owns a total of 51,248 A shares and 262,236 B shares as treasury shares, corresponding to 2.13% of the share capital.                                        
Details of each transaction are included as appendix.

Copenhagen, 26 October 2026

Contact persons:
Head of Investor Relations, Martin Dunwoodie, tel. +45 3363 3484
Head of Media Relations, Jesper Lov, tel. +45 6114 1521

Page 1 of 1

Attachments

• Announcement – Transactions in connection with share buy-back program – week 43 2026
• Daily transactions in connection with share buy-back program – week 43 2026

Stem.l
FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	SThree Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Joint Broker to SThree Plc
(d)        Date dealing undertaken:	23rd October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchase	19,560	297	289.5
Ordinary shares	Sales	19,560	297	289.5

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	26th October 2026
Contact name:	Priyali Bhattacharjee
Telephone number:	+91-9768034903

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

CERTIFICATE MATURITY	261028
FIXED RATE (STEERING RATE + 10 b.p.)	1.85 %
VOLUME BOUGHT	25.0 BLN
TRADE DAY	261026
SETTLEMENT DAY	261027

To Nasdaq Copenhagen

26 October 2026

Financial calendar 2027 for the companies of the Nykredit Group

11 February
Publication of Annual Reports 2026 and announcements of Financial Statements of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group

18 March
Annual General Meeting of Totalkredit A/S, Sundkrogsgade 25, DK-2150 Nordhavn.

18 March
Annual General Meeting of Nykredit Bank A/S, Sundkrogsgade 25, DK-2150 Nordhavn.

18 March
Annual General Meeting of Nykredit Realkredit A/S, Sundkrogsgade 25, DK-2150 Nordhavn.

5 May
Publication of Q1 Interim Report 2027 of the Nykredit Realkredit Group.

19 August
Publication of H1 Interim Reports 2027 of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group.

4 November
Publication of Q1-Q3 Interim Report 2027 of the Nykredit Realkredit Group.
                                                                                                                                           

Contact
Nykredit Press Relations, tel +45 31 21 06 39

Attachment

• Financial calendar 2027 for the companies of the Nykredit Group

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Pollen Street Group Limited
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Joint Broker to Pollen Street Group Limited
(d)        Date dealing undertaken:	23rd October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchases	1,000	910	908
Ordinary shares	Sales	2,192	929	927

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION
        
(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	26th October 2026
Contact name:	Priyali Bhattacharjee
Telephone number:	+91-9768034903

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Gamma Communications Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Joint Broker to Gamma Communications Plc
(d)        Date dealing undertaken:	23rd October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchases	131,730	1091.5	1091
Ordinary shares	Sales	111,730	1091	1091

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION
        
(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	26th October 2026
Contact name:	Priyali Bhattacharjee
Telephone number:	+91-9768034903

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

To Nasdaq Copenhagen

26 October 2026

Financial calendar 2027 for the companies of the Nykredit Group

11 February
Publication of Annual Reports 2026 and announcements of Financial Statements of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group

18 March
Annual General Meeting of Totalkredit A/S, Sundkrogsgade 25, DK-2150 Nordhavn.

18 March
Annual General Meeting of Nykredit Bank A/S, Sundkrogsgade 25, DK-2150 Nordhavn.

18 March
Annual General Meeting of Nykredit Realkredit A/S, Sundkrogsgade 25, DK-2150 Nordhavn.

5 May
Publication of Q1 Interim Report 2027 of the Nykredit Realkredit Group.

19 August
Publication of H1 Interim Reports 2027 of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group.

4 November
Publication of Q1-Q3 Interim Report 2027 of the Nykredit Realkredit Group.
                                                                                                                                           

Contact
Nykredit Press Relations, tel +45 31 21 06 39

Attachment

• Financial calendar 2027 for the companies of the Nykredit Group